Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy

Overview

Journal Int J Breast Cancer

Publisher Wiley

Date 2012 Feb 2

PMID 22295242

Citations 65

Authors

Parvin F Peddi

Matthew J Ellis

Cynthia Ma

Affiliations

Soon will be listed here.

Abstract

Triple negative breast cancer is an aggressive form of breast cancer with limited treatment options and is without proven targeted therapy. Understanding the molecular basis of triple negative breast cancer is crucial for effective new drug development. Recent genomewide gene expression and DNA sequencing studies indicate that this cancer type is composed of a molecularly heterogeneous group of diseases that carry multiple somatic mutations and genomic structural changes. These findings have implications for therapeutic target identification and the design of future clinical trials for this aggressive group of breast cancer.

Citing Articles

Tumor-Intrinsic Enhancer of Zeste Homolog 2 Controls Immune Cell Infiltration, Tumor Growth, and Lung Metastasis in a Triple-Negative Breast Cancer Model.

Monterroza L, Parrilla M, Samaranayake S, Rivera-Rodriguez D, Yoon S, Bommireddy R Int J Mol Sci. 2024; 25(10).

PMID: 38791429 PMC: 11121204. DOI: 10.3390/ijms25105392.

Mammary Glands of Women, Female Dogs and Female Rats: Similarities and Differences to Be Considered in Breast Cancer Research.

Ferreira T, Gama A, Seixas F, Faustino-Rocha A, Lopes C, Gaspar V Vet Sci. 2023; 10(6).

PMID: 37368765 PMC: 10303014. DOI: 10.3390/vetsci10060379.

Effects of β-caryophyllene and oxygen availability on cholesterol and fatty acids in breast cancer cells.

Frost C, Ramirez-Mata A, Khattri R, Merritt M, Frost S PLoS One. 2023; 18(3):e0281396.

PMID: 36893152 PMC: 9997903. DOI: 10.1371/journal.pone.0281396.

Stabilization of c-Myc by the atypical cell cycle regulator, Spy1, decreases efficacy of breast cancer treatments.

Ferraiuolo R, Fifield B, Hamm C, Porter L Breast Cancer Res Treat. 2022; 196(1):17-30.

PMID: 36029387 DOI: 10.1007/s10549-022-06715-z.

Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC).

Chaudhuri A, Kumar D, Dehari D, Singh S, Kumar P, Bolla P Pharmaceuticals (Basel). 2022; 15(5).

PMID: 35631368 PMC: 9143332. DOI: 10.3390/ph15050542.

References

Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P . How basal are triple-negative breast cancers?. Int J Cancer. 2008; 123(1):236-40. DOI: 10.1002/ijc.23518. View

Fan C, Oh D, Wessels L, Weigelt B, Nuyten D, Nobel A . Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006; 355(6):560-9. DOI: 10.1056/NEJMoa052933. View

Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adelaide J . Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 2006; 66(9):4636-44. DOI: 10.1158/0008-5472.CAN-06-0031. View

Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen P . Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res. 2008; 14(12):3916-25. DOI: 10.1158/1078-0432.CCR-07-4953. View

Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M . Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res. 2008; 10(6):R101. PMC: 2656897. DOI: 10.1186/bcr2204. View

Dent R, Hanna W, Trudeau M, Rawlinson E, Sun P, Narod S . Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2008; 115(2):423-8. DOI: 10.1007/s10549-008-0086-2. View

Foulkes W, Smith I, Reis-Filho J . Triple-negative breast cancer. N Engl J Med. 2010; 363(20):1938-48. DOI: 10.1056/NEJMra1001389. View

Richardson A, Wang Z, De Nicolo A, Lu X, Brown M, Miron A . X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006; 9(2):121-32. DOI: 10.1016/j.ccr.2006.01.013. View

Futreal P, Liu Q, Cochran C, Harshman K, Tavtigian S, Bennett L . BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994; 266(5182):120-2. DOI: 10.1126/science.7939630. View

10.

Silver D, Richardson A, Eklund A, Wang Z, Szallasi Z, Li Q . Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010; 28(7):1145-53. PMC: 2834466. DOI: 10.1200/JCO.2009.22.4725. View

11.

Foulkes W, Stefansson I, Chappuis P, Begin L, Goffin J, Wong N . Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003; 95(19):1482-5. DOI: 10.1093/jnci/djg050. View

12.

Finn R, Dering J, Ginther C, Wilson C, Glaspy P, Tchekmedyian N . Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007; 105(3):319-26. DOI: 10.1007/s10549-006-9463-x. View

13.

Moulder S . Does the PI3K pathway play a role in basal breast cancer?. Clin Breast Cancer. 2010; 10 Suppl 3:S66-71. DOI: 10.3816/CBC.2010.s.014. View

14.

Speers C, Tsimelzon A, Sexton K, Herrick A, Gutierrez C, Culhane A . Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res. 2009; 15(20):6327-40. PMC: 2763053. DOI: 10.1158/1078-0432.CCR-09-1107. View

15.

Li X, Lewis M, Huang J, Gutierrez C, Osborne C, Wu M . Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008; 100(9):672-9. DOI: 10.1093/jnci/djn123. View

16.

Juul N, Szallasi Z, Eklund A, Li Q, Burrell R, Gerlinger M . Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol. 2010; 11(4):358-65. DOI: 10.1016/S1470-2045(10)70018-8. View

17.

Tutt A, Robson M, Garber J, Domchek S, Audeh M, Weitzel J . Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010; 376(9737):235-44. DOI: 10.1016/S0140-6736(10)60892-6. View

18.

Millikan R, Newman B, Tse C, Moorman P, Conway K, Dressler L . Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2007; 109(1):123-39. PMC: 2443103. DOI: 10.1007/s10549-007-9632-6. View

19.

Fong P, Boss D, Yap T, Tutt A, Wu P, Mergui-Roelvink M . Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361(2):123-34. DOI: 10.1056/NEJMoa0900212. View

20.

Gonzalez-Angulo A, Timms K, Liu S, Chen H, Litton J, Potter J . Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011; 17(5):1082-9. PMC: 3048924. DOI: 10.1158/1078-0432.CCR-10-2560. View